Compare Heron Therapeutics Inc (HRTX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while NEOS S&P 500 High Income ETF trades at $54.02 (market cap $12.51B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 169× Heron Therapeutics Inc's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| HRTX | SPYI | |
|---|---|---|
Market Cap | $74.04M | $12.51B |
Volume | 3,668,095 | 2,751,602 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $54.42 |
52-Week Low | $0.27 | $47.98 |
Typical Hold Time | 35 Days | 57 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SPYI trades at $54.01, down 0.13% with a bullish technical signal from moving averages. The ETF shows strong institutional interest as a covered-call income vehicle, though recent news highlights concerns about principal erosion from high-yield strategies. Technical indicators show RSI at overbought levels while support and resistance cluster around $54.
The outlook remains mixed with strong income generation potential offset by capital preservation risks. Recent coverage emphasizes the trade-off between high monthly distributions and potential long-term principal decline, requiring careful consideration for retirement income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
